Adjusted EBITDA guidance for FY2025 has been increased to $188 million, up from the $173 million midpoint previously provided. This includes an $8 million gain related to the Fortress contingent ...
Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results